Immunotherapy for the treatment of metastatic small cell lung cancer: Focus on pembrolizumab

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA. Cancer J Clin. 2018;68(6):394–424. .
   PubMed Web of Science ®Google Scholar
• Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?—a review. Transl Lung Cancer Res. 2016;5(1):26–38.
   PubMed Web of Science ®Google Scholar
• George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47–53. .
   PubMed Web of Science ®Google Scholar
• Oronsky B, Reid TR, Oronsky A, et al. What’s new in SCLC? A review. Neoplasia. 2017;19(10):842–847.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians guideline. J Clin Oncol. 2015;33(34):4106–4111. .
   PubMed Web of Science ®Google Scholar
• Artal CÁ, Dómine Gómez M, Font Pous A, et al. SEOM clinical guidelines for the treatment of small-cell lung cancer. Clin Transl Oncol. 2008;224(1):27–31. .
   Google Scholar
• Frόh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl_6):99–105. .
   Google Scholar
• Rossi A, Sacco PC, Sgambato A, et al. Optimal drugs for second-line treatment of patients with small-cell lung cancer. Expert Opin Pharmacother. 2016;17(7):969–976. .
   PubMed Web of Science ®Google Scholar
• Goetze TO. Immunotherapy: a new era in small-cell lung cancer. Lancet. 2019 Nov 23;394(10212):1884–1885.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. CASPIAN investigators durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929–1939
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019 Mar 1;37(7):537–546.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Va P, Raftopoulos H, et al. KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497–1508.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540–1550.
   PubMed Web of Science ®Google Scholar
• Barone A, Hazarika M, Theoret MR, et al. FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma. Clin Cancer Res. 2017 Oct 1;23(19):5661–5665.
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Psyrri A, et al. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 Nov 23;394(10212):1915–1928.
   PubMed Web of Science ®Google Scholar
• Lundgren KT, Farina MS, Bellmunt J. Pembrolizumab in the treatment of advanced urothelial cancer. Future Oncol. 2017 Dec;13(30):2745–2758.
   PubMed Web of Science ®Google Scholar
• Shitara K, Özgüroğlu M, Bang YJ, et al. KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392(10142):123–133.
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019 Oct 3;134(14):1144–1153.
   PubMed Web of Science ®Google Scholar
• Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019 Dec 1;37(34):3291–3299.
   PubMed Web of Science ®Google Scholar
• Marcus L, Lemery SJ, Keegan P, et al. Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019 Jul 1;25(13):3753–3758.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 Jun 25;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Byron SA, Aldrich J, et al. A prospective pilot study of genome wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy. PLoS One. 2017;12(6):e0179170. .
   PubMed Web of Science ®Google Scholar
• Dudley JC, Lin MT, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22(4):813–820.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Callahan MK, Awad MM, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2018;33(5):853. .
   PubMed Web of Science ®Google Scholar
• Ishii H, Azuma K, Kawahara A, et al. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol. 2015;10(3):426–430. .
   PubMed Web of Science ®Google Scholar
• Maddison P, Newsom-Davis J, Mills KR, et al. Favourable prognosis in Lambert–Eaton myasthenic syndrome and small cell lung carcinoma. Lancet. 1999;353(9147):117–118.
   PubMed Web of Science ®Google Scholar
• Gelsomino F, Lamberti G, Parisi C, et al. The evolving landscape of immunotherapy in small-cell lung cancer: a focus on predictive biomarkers. Cancer Treat Rev. 2019 Sep;79:101887.
   PubMed Web of Science ®Google Scholar
• Boumber Y. Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer. J Thorac Dis. 2018;10(8):4689–4693.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. .
   PubMed Web of Science ®Google Scholar
• Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1.
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ladoire S, Coukos G, et al. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol. 2015;26(9):1813–1823.
   PubMed Web of Science ®Google Scholar
• Calles A, Aguado G, Sandoval C, et al. The role of immunotherapy in small cell lung cancer. Clin Transl Oncol. 2019 Aug;21(8):961–976.
   PubMed Web of Science ®Google Scholar
• Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740–3748. .
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–895. .
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ott PA, Zugazagoitia J, et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): first report of a randomized expansion cohort from CheckMate 032. J Clin Oncol. 2017;35(15_suppl):8503. .
   Google Scholar
• National Comprehensive Cancer Network. Small cell lung cancer (Version 2.2018). https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. cited 2018 Jun 15
   Google Scholar
• Horn L, Reck M, Gettinger SN, et al. CheckMate 331: an open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC). J Clin Oncol. 2016;34(15_suppl):8578. .
   Google Scholar
• Ready N, Owonikoko TK, Postmus PE, et al. CheckMate 451: a randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC). J Clin Oncol. 2016;34(25):2980–2987. .
   PubMedGoogle Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. .
   PubMed Web of Science ®Google Scholar
• Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015 Oct 1;21(19):4286–4293.
   PubMed Web of Science ®Google Scholar
• Scapin G, Yang X, Prosise WW, et al. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol. 2015 Dec;22(12):953–958.
   PubMed Web of Science ®Google Scholar
• Quast I, Lunemann JD. Fc glycan-modulated immunoglobulin G effector functions. J Clin Immunol. 2014 Jul;34(Suppl 1):S51–5.
   PubMed Web of Science ®Google Scholar
• Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016;12(10):1247–1253.
   PubMed Web of Science ®Google Scholar
• Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005 Jul 18;202(2):231–237.
   PubMed Web of Science ®Google Scholar
• Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008 Aug;224(1):166–182.
   PubMedGoogle Scholar
• Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007 Mar;8(3):239–245.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26(1):677–704.
   PubMed Web of Science ®Google Scholar
• Sathish JG, Johnson KG, Fuller KJ, et al. Constitutive association of SHP-1 with leukocyte-associated Ig-like receptor-1 in human T cells. J Immunol. 2001 Feb 1;166(3):1763–1770.
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp; Kenilworth, NJ: [May 2 2016]. KEYTRUDA® (pembrolizumab) prescribing Information.
   Google Scholar
• Brahmer JR, Drake CG, Wollner I. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–3175.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Awad MM, Navarro A, et al. KEYNOTE-604 investigators. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020 Jul 20;38(21):2369–2379.
   PubMed Web of Science ®Google Scholar
• Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase 1b KEYNOTE-028 study. J Clin Oncol. 2017;35(34):3823–3829. .
   PubMed Web of Science ®Google Scholar
• Chung HC, Lopez-Martin J, Chuan Hao Kao St. et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE158. Presented at the 2018 ASCO Annual Meeting; June 1–5, 2018; Chicago, IL
   Google Scholar
• Chung HC, Piha-Paul SA, Ott PA, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2019 Dec 20;33850(19):S1556–0864.
   Google Scholar
• Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC). J Thorac Oncol. 2018 Sep;13(9):1393–1399. .
   PubMed Web of Science ®Google Scholar
• Welsh JW, Heymach JV, Papadimitrakopoulou VA et al. Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer. J Thorac Oncol. 2019 Oct 9;33525(19):S15560864.
   Google Scholar
• Kim YJ, Keam B, Ock CY, et al. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. Lung Cancer. 2019 Oct;136:122–128.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Shen L, Pietanza MC. KEYNOTE-604: phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC). AnnOncol. 2017;28(suppl_5). mdx386.008. p.541
   Google Scholar